Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma

Fig. 7

Identification of CpGs associated with progress/metastasis in ccRCC. a Venn-diagram showing overlap of CpGs that were differently methylated compared with TF tissue, in more than 70% of samples in each ccRCC group; M0-PF; M0-P and M1. The 172 commonly DM-CpGs in the M0-P and M1 groups were defined as a Promoter Methylation Classification (PMC) panel. Selected GO-terms associated with hyper- and hypomethylated genes in PMC panel are listed. b-c Kaplan-Meier Cumulative incidence of progress (CIP) (b) in 87 non-metastatic ccRCC patients (c) in 230 non-metastatic ccRCC patients in the validation TCGA-KIRC cohort. d-f Box-plots of selected DM-CpGs in promoter regions of genes associated with progress (d) SMAD6 (e) SOCS3 and (f) MX2. *p < 0.05. g-i Box-plots of mRNA levels for (g) SMAD6, (h) SOCS3 and (i) MX2. Differences in methylation and mRNA levels between groups were analysed using Mann-Whitney U-test

Back to article page
\